SCHEMBL30983842

SCHEMBL30983842

CC1(Oc2ncnc(NCCc3cccnc3)c2N)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4C Q9H3R0 1/20 0.46
▸ TLR8 Q9NR97 1/20 0.39
▸ TLR7 Q9NYK1 1/20 0.39
▸ GALR3 O60755 1/20 0.39
▸ GBA1 P04062 1/20 0.38
▸ OGA O60502 1/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ SLC29A1 Q99808 1/20 0.37
▸ PIK3CD O00329 1/20 0.36
▸ PDPK1 O15530 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ PDE4A P27815 1/20 0.36
▸ PDE4B Q07343 1/20 0.36
▸ PDE4D Q08499 1/20 0.36
▸ JAK3 P52333 1/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ CHRNA7 P36544 1/20 0.35
▸ F2 P00734 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30983996 0.88 MAPK1 (0.46) GALR3RAB9ASLC29A1NPC1SMN1; SMN2
SCHEMBL30984268 0.81 HTT (0.48) TLR8TLR7GALR3RAB9ANPC1
SCHEMBL30983865 0.78 EGFR (0.44) KDM4CGALR3RAB9AKDM4ESMN1; SMN2
SCHEMBL30983918 0.73 MAPK1 (0.49) KDM4CSMN1; SMN2HTT
SCHEMBL31321978 0.70 TAAR1 (0.38) GALR3NPC1JAK3F2PRSS1
SCHEMBL30984051 0.70 TAAR1 (0.38) GALR3NPC1JAK3F2PRSS1
SCHEMBL30984026 0.70 TAAR1 (0.38) GALR3NPC1JAK3F2PRSS1
SCHEMBL30983967 0.70 RECQL (0.42) RAB9AKDM4ENPC1L3MBTL1SMN1; SMN2
SCHEMBL30850528 0.68 HTT (0.48) KDM4CGBA1RAB9ASLC29A1KDM4E
SCHEMBL20119357 0.68 HTT (0.48) KDM4CGBA1RAB9ASLC29A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed
Send feedback